Brands
The House of Abhinandan Lodha spreads the light of Ayodhya across the world
Mumbai – With a series of grand events at iconic locations in Dubai, New York, and Delhi NCR, HoABL showcased the immense potential of Ayodhya – the symbol of national pride, inviting global participation in Ayodhya’s promising future. The events highlighted the importance of connecting the Indian diaspora with their heritage and cementing Ayodhya’s rise as the global spiritual capital.
This global activation is in line with the Central and State Government’s plan to transform Ayodhya into a Global spiritual and cultural hub. By presenting Ayodhya’s rich legacy at iconic locations, HoABL underscored the city’s significance and growth potential.
The event highlights included an immersive display at the largest frame in the world, Dubai Frame, standing tall at 150 meters. Dubai Frame is one of Dubai’s most iconic structures and it signifies a bridge between the past and the present, so it was a fitting destination to honour Ayodhya’s tradition while heralding its future through an immersive augmented reality display, In Times Square, New York City, a video display and on-ground activation brought Ayodhya’s heritage to the heart of NYC, connecting a global audience to the splendor of Ayodhya. Additionally, a spectacular drone-show illuminated the skies of Delhi NCR, celebrating Ayodhya’s historical and spiritual significance, showcasing progress innovation and tradition.
The House of Abhinandan Lodha chairman Abhinandan Lodha said, “It is our honor to be able to showcase the glory of Ayodhyaji on a world stage. By showcasing Ayodhyaji’s heritage and spiritual significance at global landmarks we are connecting the Indian diaspora with their roots. This global launch is another opportunity for the Indian Diaspora to buy as a lot of them missed the previous opportunity in January 2024 as the 1.6 million sq ft of plotted land offered was snapped up by customers within 48 hours. We invite Indians worldwide to invest in land at Ayodhya, creating a legacy that honors our past and builds a promising future. Our mission is to elevate Ayodhya to its rightful place as a global spiritual capital, and today, we have taken a significant step in that direction.”
In Jan 2024 this year Shri. Amitabh Bachchan bought land at The Sarayu™, a 7-star branded land development project by The House of Abhinandan Lodha. Speaking about his investment in The Sarayu™, Mr. Amitabh Bachchan said, “I am looking forward to embark on this journey with The House of Abhinandan Lodha for The Sarayu in Ayodhya, a city that holds a special place in my heart. The timeless spirituality and cultural richness of Ayodhya have forged an emotional connection that transcends geographical boundaries. I am looking forward to building my home in the global spiritual capital.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
